Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

David Taft, PhD, Tarang Vora, MS, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Joseph Morgan, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Manoj Maniar, PhD

Blood (2018) 132 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2018-99-118463

Published: 2018

Journal Articles

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

John Roboz, Shyamala C. Navada, MD, Sool Yeon Cho, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2018-99-115169

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Manoj Maniar, PhD, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, David Taft, PhD

Blood (2018) 132 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2018-99-116982

Published: 2018

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Lewis R. Silverman, MD

Blood (2016) 128 (22): 4324.

https://doi.org/10.1182/blood.V128.22.4324.4324

Published: 2016

Journal Articles

Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models

Maurizio Zangari, MD, Ikjae Shin, PhD, Antonio Branca, MD, Hanna Yoo, MS, Sophia Fallo, Faith E Davies, MD, Benjamin Hoffman, PhD, Steven M. Fruchtman, MD, Donghoon Yoon, PhD

Blood (2016) 128 (22): 5664.

https://doi.org/10.1182/blood.V128.22.5664.5664

Published: 2016

Journal Articles

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Steven M. Fruchtman, MD, Abdullah Mahmood Ali, PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Benjamin Hoffman, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Azra Raza, MD

Blood (2016) 128 (22): 5535.

https://doi.org/10.1182/blood.V128.22.5535.5535

Published: 2016

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Francine M Foss, MD, Steven M Horwitz, MD, Lauren Pinter-Brown, MD, Andre Goy, MD, Barbara Pro, MD, Bertrand Coiffier, MD, PhD, Leslie Popplewell, M.D., Kerry Joanne Savage, MD, BSc, MSc, Andrei Shustov, MD, Jasmine M. Zain, MD, Tony Koutsoukos, Steven M. Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2010) 116 (21): 1762.

https://doi.org/10.1182/blood.V116.21.1762.1762

Published: 2010

Journal Articles

Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Owen A O'Connor, MD, PhD, Corinne Haouin, MD, Pier Luigi Zinzani, MD, PhD, Christian Gisselbrecht, MD, Francine M Foss, MD, Kerry Joanne Savage, MD, BSc, MSc, Barbara Pro, MD, Lauren Pinter-Brown, MD, Nancy L. Bartlett, MD, Steven M Horwitz, MD, Eric D Jacobsen, MD, Tony Koutsoukos, Steven M. Fruchtman, MD, Bertrand Coiffier, MD, PhD

Blood (2010) 116 (21): 4881.

https://doi.org/10.1182/blood.V116.21.4881.4881

Published: 2010

Journal Articles

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Andrei Shustov, MD, Barbara Pro, MD, Christian Gisselbrecht, MD, Leslie Popplewell, M.D., Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Jasmine M. Zain, MD, Faith Young, Richard R. Furman, MD, Steven M. Fruchtman, MD, Steven M Horwitz, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4882.

https://doi.org/10.1182/blood.V116.21.4882.4882

Published: 2010

Journal Articles

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

Andre Goy, MD, Barbara Pro, MD, Kerry Joanne Savage, MD, BSc, MSc, Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Eric D Jacobsen, MD, Faith Young, Michael Crump, MD, FRCPC, Hossein Borghaei, DO, Brian Link, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 1753.

https://doi.org/10.1182/blood.V116.21.1753.1753

Published: 2010

Journal Articles

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Steven M Horwitz, Youn H. Kim, MD, Francine M Foss, MD, Jasmine M. Zain, MD, Patricia Myskowski, MD, Mary Jo Lechowicz, MD, David C. Fisher, MD, Andrei Shustov, MD, Nancy L. Bartlett, MD, Maria L Delioukina, MD, Tony Koutsoukos, PhD, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD, Madeleine Duvic, MD

Blood (2010) 116 (21): 2800.

https://doi.org/10.1182/blood.V116.21.2800.2800

Published: 2010

Journal Articles

Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

Celia L. Grosskreutz, MD, Ronald Egan, Eileen Scigliano, MD, Steven M. Fruchtman, MD, Luis M. Isola, MD

Blood (2004) 104 (11): 1254.

https://doi.org/10.1182/blood.V104.11.1254.1254

Published: 2004

Journal Articles

Imatinib Mesylate (GLEEVEC®) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial.

Richard T. Silver, MD, Steven M. Fruchtman, MD, Eric J. Feldman, MD, Jerry L. Spivak, MD, August J. Salvado, MD

Blood (2004) 104 (11): 656.

https://doi.org/10.1182/blood.V104.11.656.656

Published: 2004

NARROW

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

Imatinib Mesylate (GLEEVEC®) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only